Abstract
We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.
| Original language | English |
|---|---|
| Pages (from-to) | 535-542 |
| Number of pages | 8 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 26 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2003 |
Fingerprint
Keywords
- Aggressive non-Hodgkin lymphoma
- Cisplatin
- First-line chemotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
P-CHOP : Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study. / Cocconi, Giorgio; Franciosi, Vittorio; Dodero, Anna; Bologna, Alessandra; Vasini, Giovanna; De Lisi, Vincenzo; Di Blasio, Beatrice; Ceci, Guido; Camisa, Roberta; Cascinu, Stefano.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 6, 12.2003, p. 535-542.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - P-CHOP
T2 - Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study
AU - Cocconi, Giorgio
AU - Franciosi, Vittorio
AU - Dodero, Anna
AU - Bologna, Alessandra
AU - Vasini, Giovanna
AU - De Lisi, Vincenzo
AU - Di Blasio, Beatrice
AU - Ceci, Guido
AU - Camisa, Roberta
AU - Cascinu, Stefano
PY - 2003/12
Y1 - 2003/12
N2 - We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.
AB - We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.
KW - Aggressive non-Hodgkin lymphoma
KW - Cisplatin
KW - First-line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0348134798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0348134798&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000037110.25789.62
DO - 10.1097/01.coc.0000037110.25789.62
M3 - Article
C2 - 14663368
AN - SCOPUS:0348134798
VL - 26
SP - 535
EP - 542
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 6
ER -